Interleukin‐17 alleviates erastin‐induced alveolar bone loss by suppressing ferroptosis via interaction between <scp>NRF2</scp> and <scp>p‐STAT3</scp>

Abstract

IL-17 administration conferred resistance to erastin-induced osteoblast ferroptosis and osteogenesis. The possible mechanism may involve p-STAT3 directly interacting with NRF2.